Randomized Trial: Efficacy of Glecaprevir and Pibrentasvir in Patients with Chronic HCV Genotype 1 Patients After Treatment Failure with NS5A Inhibitor Plus Sofosbuvir Therapy
22 Jan, 2020 | 09:11h | UTCEditorial: Retreatment Options for Patients Who Failed Direct-Acting Antiviral Regimens Containing NS5A Inhibitors: Is Glecaprevir/Pibrentasvir a Valid and Robust Option? (free)
Source: EvidenceAlerts
Related Commentary on Twitter
16 weeks treatment with G/P produced sustained virologic response 12 weeks after treatment in >90% of chronic #HCV genotype 1 patients https://t.co/YGM81urXpm pic.twitter.com/g1OtzeKQsL
— Gastroenterology (@AGA_Gastro) November 27, 2019